Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii symbols : TAK save search
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
Published: 2023-09-11 (Crawled : 12:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 1.31%
H: 0.91%
C: 0.52%
tak-279 active positive treatment topline results study
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Published: 2022-12-13 (Crawled : 12:20) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 2.21%
H: 0.66%
C: -0.07%
ndi-0348 acquire therapeutics potential
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: -1.16%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
ARCT 4 | $25.94 -1.44% 170K
|
Health Technology
|
| O: 6.93%
H: 1.13%
C: -8.47%
arct-154 trial results
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 1.17%
H: 0.68%
C: 0.27%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
ARCT 4 | $25.94 -1.44% 170K
|
Health Technology
|
| O: -20.04%
H: 28.04%
C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $25.94 -1.44% 170K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
Published: 2021-07-28 (Crawled : 20:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.42%
H: 2.14%
C: 1.72%
food narcolepsy therapy breakthrough therapy drug designation
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Published: 2021-07-28 (Crawled : 15:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 0.42%
H: 2.14%
C: 1.72%
JNJ | News | $147.17 0.98% 3.2M
|
Health Technology
|
| O: 0.04%
H: 0.38%
C: -0.32%
ARCT 4 | $25.94 -1.44% 170K
|
Health Technology
|
| O: -0.19%
H: 6.93%
C: 6.54%
phase 2 approval
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Published: 2021-04-28 (Crawled : 13:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.95%
H: 0.84%
C: 0.48%
ARWR | $22.1 -2.26% 390K
|
Health Technology
|
| O: 0.01%
H: 2.92%
C: 1.92%
disease liver disease treatment fibrosis liver
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
Published: 2021-01-28 (Crawled : 15:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: 1.54%
H: 1.63%
C: 0.73%
positive therapy results positive results
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
Published: 2021-01-21 (Crawled : 15:00) - biospace.com/
TAK | News | $13.19 0.23% 740K
|
Health Technology
|
| O: -0.97%
H: 0.62%
C: -0.63%
MRNA S | $101.17 -0.81% 1.1M
|
Health Technology
|
| O: 0.11%
H: 9.36%
C: 6.15%
covid vaccine phase 3 phase 1 phase 2
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.